methylation; metabolic syndrome; visceral adipose tissue; epigenetics; obesity EXCESS ACCUMULATION OF FAT tissue in the intra-abdominal cavity [visceral adipose tissue (VAT)] is associated with alterations in insulin sensitivity, blood pressure, and the plasma lipid profile (16, 23) . This constellation of risk factors defines the metabolic syndrome (MetS) (8) . These features independently or collectively contribute to a high risk for chronic diseases that are major causes of death worldwide (26) . Yet not all obese individuals are characterized by the MetS, and even the severely obese population is heterogeneous regarding the cardiovascular disease risk profile (14) .
Heritability of obesity as assessed by a high body mass index (BMI) has long been recognized (38) . Similarly, heritability of the MetS and its components was also demonstrated (40) . However, single nucleotide polymorphisms (SNPs) so far associated with MetS explain only a small part of the variance of the heterogeneous phenotype (15, 28) , and the pathogenesis of these conditions likely involves multiple interactions among behavioral, environmental, and genetic factors. Many more genetic variations remain to be identified, and complementary phenomena have been proposed to explain heritability of obesity and obesity-related metabolic complications (38) .
Obesity and metabolic disorders such as the MetS appear as polygenic conditions affected by environmental factors (22) . Epigenetic marks, which are traditionally referred to as heritable changes in gene expression not due to alteration in DNA sequence (32) , are altered by environmental factors and thus represent potential mechanisms through which the environment may cause phenotypic variation (9) . Analysis of epigenetic marks in relation to MetS becomes imperative. Most human methylation profiles have been performed on DNA from easily accessible tissues (e.g., leukocytes), and tissuespecific DNA methylation was noted for various genes (1, 19, 31) . Recent technical advances allow assessment of CpG site methylation levels on a genome-wide scale. Several lines of evidence point toward a dysregulation of VAT function with the development of obesity and obesity-related metabolic complications (33) ; assessment of gene methylation in VAT is needed.
The current study aimed at the identification of biological pathways potentially altered in VAT of severely obese men with MetS compared with severely obese men without MetS. Using a combination of genome-wide differential methylation analysis followed by pathway analysis, we provide potential avenues for research on obesity-related metabolic complications in severely obese individuals.
METHODS AND PROCEDURES
Patient selection. Between June 2000 and July 2012, 1,906 severely obese men (n ϭ 597) and women (n ϭ 1,309) undergoing biliopancreatic diversion with duodenal switch (21) at the Quebec Heart and Lung Institute (Quebec City, Quebec, Canada) were re-cruited. VAT was obtained as previously described (36) from a subset of 14 men (BMI Ͼ40 kg/m 2 ) free of metabolic diseases such as Type 2 diabetes, cardiomyopathy, or endocrine disorders. Seven of them were affected by MetS (MetSϩ group) and were matched for age, BMI, and smoking status to obese individuals without MetS (MetSϪ group, n ϭ 7). None of them were taking medication to treat MetS features. The presence of MetS was determined by the National Cholesterol Education Program Adult Treatment Panel III guidelines when an individual fulfilled three or more criteria (8) . The study was approved by the Université Laval ethics committee and performed in accordance with the principles of the Declaration of Helsinki. Tissue banking and the severely obese cohort were approved by the research ethics committees of Quebec Heart and Lung Institute. All individuals provided written informed consent before their inclusion. Body weight, height, waist girth, and resting systolic (SBP) and diastolic (DBP) blood pressure were measured preoperatively by standardized procedures. BMI was calculated as weight in kilograms divided by height in meters squared. Plasma triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), total-C/HDL-C ratio, and glucose and insulin concentrations were measured as previously described (36) . Plasma C-reactive protein (CRP) levels were obtained with a high-sensitivity CRP immunoassay using a monoclonal antibody coated with polystyrene particles. The assay was performed with a BN ProSpec nephelometer (Dade Behring, Mississauga, Ontario, Canada) according to manufacturer's recommendations.
DNA methylation analysis. Genomic DNA was extracted from 200 mg of the VAT using the DNeasy Blood & Tissue kit (QIAGEN, Mississauga, Ontario, Canada), as recommended by the manufacturer, and quantified using both NanoDrop Spectrophotometer (Thermo Scientific, Wilmington, DE) and PicoGreen DNA methods. Bisulfite conversion was conducted on 1 g of DNA, and quantitative DNA methylation analysis was carried out at the McGill University and Génome Québec Innovation Centre (Montreal, Canada). Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA) were processed according to the manufacturer's instructions. The BeadChip interrogates Ͼ485,000 methylation sites at single-nucleotide resolution.
Methylation data were visualized and analyzed using the GenomeStudio software version 2011.1 (Illumina) and the Methylation Module. Array data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (accession number GSE54776). None of the samples were excluded following quality control steps assessed by bisulfite conversion, extension, staining, hybridization, target removal, negative and nonpolymorphic control probes. Methylation levels [beta values (␤)] were estimated as the ratio of signal intensity of the methylated alleles to the sum of methylated and unmethylated intensity signals of the alleles [␤ value ϭ C/(T ϩ C)]. The ␤ values vary from 0 (no methylation) to 1 (100% methylation). Infinium HumanMethylation450 BeadChip contained two probe types; type-specific normalization was conducted using internal control probes with the GenomeStudio Methylation Module normalization algorithm. CpG sites with a detection P value Ͼ 0.05 were removed from analysis. Differences in methylation levels between MetSϩ and MetSϪ groups (mean ␤ values) were tested with the Illumina Custom model. False discovery rate-corrected (FDRcorrected; FDR cutoff of Յ 5%) P values and DiffScores were computed. DiffScore is a differential methylation score calculated from P values and differences in ␤ (delta ␤) between the two groups and was used here as the main statistical results for comparison between groups.
A mass spectrometry-based approach (EpiTYPER; Sequenom, San Diego, CA) was used to validate methylation levels of CpG site showing 1) differential methylation and 2) located in nonpolymorphic regions from DGKZ, GSTM5, LRP1B, PEAK1, RPTOR, and ZNF234 genes. This approach allows for measurement of several CpG sites within a region; available surrounding CpG sites corresponding to CpG sites on the BeadChip were also analyzed. Genomic DNA (500 ng) was bisulfite converted with EZ DNA Methylation kit (Zymo Research), and assays were conducted according to manufacturer's recommendations at the McGill University and Génome Québec Innovation Centre (Montreal, Canada). DGKZ differentially methylated CpG site cg12856521, located at Chr11:46389249, was excluded from methylation data validation due to CpG site-containing fragments with equal or overlapping mass, making it irresolvable by mass spectrometry.
Pathway analysis. The Ingenuity Pathway Analysis (IPA) system was used to analyze potentially altered pathways from the list of differentially methylated genes between MetSϩ and MetSϪ individuals. Each gene from this list was classified according to pathways, and IPA measured the likelihood that these genes participate in a particular pathway. Using a right-tailed Fisher's exact test, IPA measured the likelihood that genes from the list participate in each pathway solely due to chance and calculated P values. Overrepresented pathways were then obtained from differential methylation analysis. Pathway analysis was conducted on both the full list of differentially methylated genes and the list of differentially methylated genes following the exclusion of differentially methylated CpG sites with SNPs located within probe sequences according to BeadChip annotation.
Statistical analysis. Clinical data are expressed as means Ϯ SD. Differences in anthropometric data, fasting plasma glucose and insulin levels, lipid profiles, blood pressure, and CRP levels between MetSϩ and MetSϪ individuals were tested by unpaired Student's t-test. Pairwise Pearson correlations were computed for all CpG site methylation levels between MetSϩ and MetSϪ groups. Similar analysis was also conducted separately for differentially methylated CpG sites. Statistical significance was defined as P Յ 0.05. Statistical analyses for the MetSϩ and MetSϪ groups were conducted with the SAS software version 9.2 (SAS Institute). Descriptive statistics for genome-wide methylation data were calculated in R version 2.14.1 (R Foundation for Statistical Computing; http://www.r-project.org).
RESULTS

Subjects' characteristics.
Subjects included in this study were middle-aged, severely obese men (38.0 Ϯ 9.5 yr, 53.2 Ϯ 6.7 kg/m 2 ). All individuals met the MetS criterion for abdominal obesity. BMI, total-C, LDL-C, and CRP levels were not significantly different (P Ͼ 0.05) between men with and without the MetS (Table 1 ). In particular, high levels of CRP were observed in both groups. Individuals from the MetSϩ group had elevated plasma fasting glucose (P ϭ 0.002) and TG (P ϭ 0.005) levels and BP (SBP, P ϭ 0.009 and DBP, P ϭ 0.04) compared with the MetSϪ group. Lower HDL-C levels (P Ͻ 0.0001) were also observed in MetSϩ vs. MetSϪ individuals.
Global methylation levels. Globally, 485,337 of the 485,577 probes (99.95%) on the array were detected. In the MetSϩ and MetSϪ groups, the fractions of low methylated CpG sites (Ͻ25%) were 37.3 and 37.4%, respectively. A larger betweengroup difference in highly methylated sites (Ͼ75%) was observed. Indeed, MetSϩ individuals showed 37.5% highly methylated CpG sites compared with 37.3% in MetSϪ. CpG site methylation levels of MetSϩ and MetSϪ groups were strongly correlated (Pearson's r ϭ 0.998, P Ͻ 2.2 ϫ 10 Ϫ16 ; Fig. 1) .
Differentially methylated CpG sites between MetSϩ and MetSϪ groups. Differential methylation analysis revealed 8,578 CpG sites exhibiting significant differences (FDR-corrected DiffScore Ն |13| ϳ P Յ 0.05) in VAT of MetSϩ vs.
MetSϪ individuals. Absolute difference in DNA methylation for those CpG sites ranged from 0.026 to 0.566 (2.6 to 56.6%); distribution is shown in Fig. 2 . Lower mean correlation level was found between MetSϩ and MetSϪ groups for those differentially methylated probes (Pearson's r ϭ 0.958, P Ͻ 2.2 ϫ 10
Ϫ16
; Fig. 3 ). Further stratification according to CpG site localization is presented in Table 2 . Among these sites, 2,071 (24.1%) were intergenic and 6,507 were assigned to 3,258 unique genes. The most significant differentially methylated probes between MetSϩ and MetSϪ along with differences in ␤ values (delta ␤) are presented in Supplemental  Tables S1 and S2. 1 From those differentially methylated CpG sites, several were located in genes known to be related to cellular growth and proliferation (PPP2R2B, PRKCA), immunity and inflammation (IL17RA, HLA-C, HLA-DRB1), and lipid metabolism (FASN, ALOX12, LRP1B, PLA1A). Strikingly, positioning of differentially methylated CpG sites highlighted regions with differential methylation, namely the GSTM gene cluster on chromosome 1p13.3 and the HLA gene cluster at 6p21.3. In addition, the RPTOR gene (17q25.3) involved in cell growth response to nutrients and insulin levels demonstrated 28 differentially methylated CpG sites.
Methylation levels of three overmethylated (GSTM5, LRP1B, and RPTOR) and three undermethylated (DGKZ, PEAK1, and ZNF234) genes were validated. Significant correlations between array and EpiTYPER data were observed for probes located in GSTM5, PEAK1, RPTOR, and ZFP234 (r ranged from 0.601 to 0.992, P Յ 0.02 for all), while a trend was observed for CpG site cg24126592 in DGKZ (r ϭ 0.462, P ϭ 0.10) and no significant correlation for CpG site located in LRP1B (r ϭ 0.362, P ϭ 0.20) (Supplemental Table S3 ). 1 The online version of this article contains supplemental material. Pathway analysis. From the list of 3,258 differentially methylated genes (6,507 CpG sites) in the MetSϩ vs. MetSϪ groups, IPA mapped 3,186 genes and classified them according to pathways and calculated P values for pathway overrepresentation in the data set. IPA revealed 41 pathways significantly overrepresented (P Ͻ 0.05) from the list of differentially methylated genes. Top overrepresented pathways were related to structural components of the cell membrane (glycerophospholipid and phospholipid metabolism), inflammation and immunity (antigen presentation and T lymphocyte apoptosis, autoimmune disease), and cell cycle regulation (cyclins and cdc42 signaling, inositol phosphate metabolism). The list of overrepresented pathways from differentially methylated genes between MetSϩ and MetSϪ individuals and associated P values is provided in Table 3 . Systematic exclusion of differentially methylated CpG sites with SNPs located within probe sequences led to similar results with overrepresented pathways in relation to inflammation and immunity (antigen presentation and T lymphocyte apoptosis) and cell cycle regulation (cyclins signaling and inositol phosphate metabolism) ( Table 3) . 
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Pathways in boldface are also overrepresented following the exclusion of differentially methylated CpG sites with SNPs located within probe sequences, as provided in annotations for the Infinium HumanMethylation450 BeadChip. Diff Meth, differentially methylated.
DISCUSSION
The current study aimed at the identification of pathways potentially altered in VAT of severely obese men developing MetS. Using a genome-wide differential methylation analysis followed by pathway analysis, we identified differences in CpG sites methylation levels between MetSϩ and MetSϪ individuals and overrepresented pathways from differentially methylated genes, thus revealing novel potential molecular pathways implicated in the pathogenesis of the MetS.
The small proportion of the variance in MetS phenotypes explained by SNPs identified in genome-wide association studies (GWAS) and other association studies (15, 28) indicates that many genetic variations remain to be discovered and that other contributors to MetS variability may exist. We conducted here a genome-wide differential methylation analysis in VAT combined with pathway analysis to identify potential targets involved in the pathogenesis of the MetS. Being at the interface between an individual's genetics and environment (9), epigenetic alterations are potential mechanisms to consider to explain how gene-environment interaction could influence conditions such as MetS (22) .
VAT was selected in the current study since abdominalvisceral obesity has been associated with alterations in insulin sensitivity, blood pressure, and the plasma lipid profile (16, 23) . Adipose tissue is known to produce and secrete many factors that play important physiological roles (34) . Dysregulated adipose tissue has been proposed to play a critical role in the development of obesity and obesity-related metabolic complications (33) . By assessing gene methylation in VAT, we aimed to identify potentially altered pathways associated with the development of obesity-related metabolic complications. For example, epigenetic mechanisms were shown to be involved in adipocyte maturation and leptin gene expression (24, 39) .
The current study provides a basic understanding of DNA methylation in VAT of severely obese individuals with and without MetS. Global methylation patterns obtained here are concordant with those obtained at the genome-wide scale in other tissues, where a high proportion of CpG sites demonstrated either high (Ͼ75%) or low (Ͻ25%) levels of methylation (3, 31) . Strong correlation in methylation levels was found here between MetSϩ and MetSϪ individuals. Similar genome-wide methylation analyses also demonstrated strong correlations of methylation levels between twins (4, 31) and unrelated individuals (2, 4) in various tissues. A low proportion of CpG sites demonstrated significant differences in methylation levels between MetSϩ and MetSϪ groups. In fact, 0.9% of the probes were overmethylated and 0.9% undermethylated in MetSϩ individuals. Together with other studies demonstrating low level of differential methylation in various conditions (11, 20, 37) , these results globally suggest that alterations of CpG site methylation levels in few specific genes or pathways may have profound impact on a given phenotype through the regulation of gene expression levels.
Differential methylation analysis between MetSϩ and MetSϪ individuals identified genes related to cellular growth and proliferation, immunity, and inflammation, and lipid metabolism among the lists of the most overmethylated and undermethylated genes. These findings on differential methylation of genes related to lipids are in accordance with associations identified in GWAS where most of the SNPs associated with the MetS were involved in lipid metabolism (15, 27) . Combining differential methylation with pathway analysis, we identified 41 overrepresented pathways from the list of 3,258 differentially methylated genes. Overrepresentation of pathways related to cell cycle regulation found here may be related to different tissue composition and biology between MetS groups. Adipocyte hypertrophy in VAT was associated with alterations in glucose and insulin (17) , lipid profile (35) , and hypertension (17) . Differences in adipocyte growth, proliferation, and differentiation between MetSϩ and MetSϪ groups might contribute to overrepresentation of pathways related to cell cycle regulation. Adipose tissue is heterogeneous regarding cell composition (18) . Low-grade inflammation and immune cell infiltration in VAT result in increased production of inflammatory cytokines and have been proposed to be associated with adipose tissue dysfunction (25) and with metabolic alterations observed in abdominally obese individuals (10) . Different levels of immune cell infiltration in VAT of MetSϩ vs. MetSϪ individuals may contribute to the overrepresentation of inflammatory and immune pathways observed here (10) . These results are strengthened by differential methylation found at the HLA gene cluster and numerically greater CRP levels observed in MetSϩ individuals. This is consistent with the underlying role of inflammation proposed in increased cardiometabolic risk and in the clustering of MetS features (7, 12, 33) .
This study has some limitations. Selection criteria included in this study and VAT availability limits the sample size. The tissue of interest here is composed of many different cell types including immune cells, which may bias results toward immunity and inflammation. Nonetheless, an interplay between cell types composing the VAT exists and may have an implication for MetS development (18) . It was thus important to assess whole VAT rather than isolated adipocytes. Questions may be raised about the validity of our results in regard to the number of differentially methylated genes identified. The fact that 33.6% (1,095) of the 3,258 differentially methylated genes were identified by two or more probes supports the validity of our results. It may be perceived that differences in methylation levels observed here might be driven by age differences between MetSϩ and MetSϪ groups (8.8 yr, nonsignificant). However, given the very small proportion of CpG sites affected and the site-and location-dependent effect of age on CpG site methylation levels (5, 29, 31) , it is unlikely that it played an important role in the present study. We acknowledge that our study focuses on CpG site methylation level without considering the potential effect on gene expression. While a general rule exists about the impact of CpG site methylation levels on gene expression, the impact of DNA methylation on gene expression seems to be site and location dependent (13, 30) . Differences in methylation levels found here thus cannot be extrapolated to differences in expression levels and disruption of specific pathways. In addition, we cannot exclude the contribution of SNPs to differences in methylation levels observed. Surrounding SNPs were shown to have an impact on CpG sites methylation level (3, 6) . Further studies are thus needed to assess the impact of surrounding SNPs on methylation levels and pathway disruption associated with differences in methylation level of specific CpG site between MetSϩ and MetSϪ individuals. The cohort used here represents an extreme obesity phenotype in men; extensive studies in other cohorts are required to extrapolate these observations to other classes of obesity or to women.
GWAS and candidate gene analysis explain a small part of the genetic variation in MetS. In the need for new approaches to identify molecular pathways involved in the development of MetS, we performed a genome-wide methylation analysis followed by pathway analysis. This study allowed the identification of differentially methylated genes and pathways in VAT between MetSϩ and MetSϪ severely obese men, thus providing potential targets likely involved in the development of the MetS.
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